Equities

Shin Nippon Biomedical Laboratories Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shin Nippon Biomedical Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,699.00
  • Today's Change23.00 / 1.37%
  • Shares traded219.60k
  • 1 Year change+4.88%
  • Beta-0.3326
Data delayed at least 15 minutes, as of Feb 18 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shin Nippon Biomedical Laboratories Ltd is a Japan-based company engaged in contract research organization (CRO) business, translational research (TR) business, and other businesses. It operates through four business segments. CRO segment includes non-clinical business using laboratory animals, cells, and bacteria to confirm the efficacy and safety of drugs under development by pharmaceutical companies, and clinical business, conducting trials to confirm efficacy and safety in humans. Translational Research segment develops nasal delivery platform technologies and conducts non-clinical and clinical testing necessary for the evaluation and approval of pharmaceuticals and others. Medipolis segment operates accommodation facilities and geothermal power generation businesses. United States Real Estate segment rents out multi-purpose industrial buildings constructed on sites owned by its subsidiary. It also undertakes administrative work and provides support for the group's operations.

  • Revenue in JPY (TTM)31.37bn
  • Net income in JPY3.99bn
  • Incorporated1973
  • Employees1.44k
  • Location
    Shin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
  • Phone+81 355655001
  • Fax+81 355656160
  • Websitehttps://snbl.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pharma Foods International Co., Ltd.66.38bn-1.88bn18.38bn613.00--1.95--0.2769-64.99-64.992,293.41324.902.021.7015.01108,280,600.00-5.746.92-16.0118.9080.3280.70-2.843.340.6512-8.210.615133.245.0133.56-88.52-11.84-0.16124.08
AnGes Inc874.12m-5.23bn24.13bn55.00--7.71--27.61-15.21-15.212.467.910.17350.34878.45---103.74-49.52-189.41-59.1636.6531.53-597.83-3,839.321.18-23.870.0174--35.8185.3181.42---29.27--
Heartseed Inc-100.00bn-100.00bn44.21bn39.00--6.14----------314.76------------------------22.15--0.00004--------------
Healios KK104.00m-2.22bn49.82bn65.00--8.73--479.00-25.70-25.700.966142.250.0067--0.4952---14.27-23.01-18.09-30.33-109.62---2,143.27-2,221.73----0.5993---81.4330.9647.65---11.70--
Shin Nippon Biomedical Laboratories Ltd31.37bn3.99bn69.78bn1.44k17.491.329.802.2295.8495.84753.611,269.670.29831.015.5921,848,400.003.739.905.3114.8251.5952.6812.5023.350.6308--0.438330.4922.5517.36-10.9614.0754.7958.49
3-D Matrix Ltd8.47bn6.47m70.18bn114.00--17.6091.678.29-2.67-2.6771.6132.901.250.98494.6174,276,300.000.0958-35.520.1222-46.1268.6759.660.0764-55.662.53--0.2619--51.1159.47-878.94---7.64--
Takara Bio Inc44.15bn-7.20bn132.58bn1.78k--1.31--3.00-59.79-59.79366.64839.160.35351.485.4924,816,750.00-5.738.66-6.129.7053.9963.76-16.2017.163.83-4.820.089831.403.535.44-29.59-22.8820.4616.27
GNI Group Ltd26.84bn-4.41bn145.55bn867.00--2.90--5.42-80.69-80.69511.58900.920.34472.184.01---9.400.5414-11.370.647574.4980.97-27.261.283.79-2.990.0941--13.6722.39-501.65--34.24--
SanBio Co Ltd0.00-3.44bn168.63bn29.00--316.25-----48.26-48.260.006.830.00----0.00-138.65-47.32-177.12-57.01-----------12.420.725-------9.02---46.04--
Peptidream Inc18.52bn-3.75bn182.34bn621.00--3.52--9.84-28.99-28.99143.24398.780.21823.753.32---4.428.02-5.869.7240.6164.82-20.2418.771.53-16.770.24850.00-60.329.66-124.97--24.52--
Data as of Feb 18 2026. Currency figures normalised to Shin Nippon Biomedical Laboratories Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

17.18%Per cent of shares held by top holders
HolderShares% Held
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 28 Nov 20252.30m5.53%
Asset Management One Co., Ltd.as of 15 Dec 20252.10m5.04%
Nomura Asset Management Co., Ltd.as of 05 Feb 2026862.90k2.07%
The Vanguard Group, Inc.as of 04 Feb 2026715.83k1.72%
Daiwa Asset Management Co. Ltd.as of 30 Jan 2026406.70k0.98%
Amova Asset Management Co., Ltd.as of 06 Feb 2026339.10k0.82%
Mellon Investments Corp.as of 06 Feb 2026179.80k0.43%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Feb 2026147.30k0.35%
BlackRock Japan Co. Ltd.as of 05 Feb 202651.10k0.12%
Charles Schwab Investment Management, Inc.as of 05 Feb 202646.33k0.11%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.